Copyright
©2012 Baishideng. All rights reserved.
World J Diabetes. Sep 15, 2012; 3(9): 161-169
Published online Sep 15, 2012. doi: 10.4239/wjd.v3.i9.161
Published online Sep 15, 2012. doi: 10.4239/wjd.v3.i9.161
Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study
Matthias Blüher, Department of Medicine, University of Leipzig, 04103 Leipzig, Germany
Ira Kurz, Kantar Health GmbH, 80687 Munich, Germany
Simone Dannenmaier, Markus Dworak, Clinical and Regulatory Affairs, Novartis Pharma GmbH, 90429 Nuremberg, Germany
Author contributions: Blüher M, Dannenmaier S and Dworak M designed research; Blüher M and Dworak M performed research; Dannenmaier S, Kurz I and Dworak M analyzed data; Blüher M, Kurz I and Dworak M wrote the paper.
Supported by Novartis Pharma GmbH
Correspondence to: Dr. Markus Dworak, MSc, Clinical and Regulatory Affairs, Novartis Pharma GmbH, Roonstr. 25, 90429 Nürnberg, Germany. markus.dworak@novartis.com
Telephone: +49-911-27313093 Fax: +49-911-27317093
Received: April 26, 2012
Revised: August 29, 2012
Accepted: September 5, 2012
Published online: September 15, 2012
Revised: August 29, 2012
Accepted: September 5, 2012
Published online: September 15, 2012
Core Tip